Oui Therapeutics is developing the world's first prescription digital therapeutic specifically designed to address suicide risk through evidence-based digital interventions. Their clinical trials aim to validate the efficacy of these therapeutics in reducing suicidal ideation and improving mental health outcomes.
Funding
$33.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Suicide is a significant public health concern, and current interventions often fall short in providing timely and accessible support to individuals at risk. Traditional mental health treatments may not be readily available or easily accessible, leading to delays in care and potentially worsening outcomes for those experiencing suicidal ideation.
Solution
Oui Therapeutics is developing prescription digital therapeutics designed to address suicide risk through evidence-based digital interventions. These therapeutics aim to provide accessible and personalized support to individuals experiencing suicidal ideation, potentially improving mental health outcomes. The company is currently conducting clinical trials to validate the efficacy of these therapeutics. The digital therapeutic approach allows for continuous monitoring and intervention, potentially bridging gaps in traditional mental healthcare.
Target Audience
The primary target audience includes individuals at risk of suicide and healthcare providers seeking innovative tools to support suicide prevention efforts.
Features
- Digital therapeutic interventions based on evidence-based practices for suicide prevention
- Designed to be accessible and personalized for individuals at risk of suicide
- Aims to reduce suicidal ideation and improve overall mental health outcomes
- Clinical trials are underway to validate the efficacy of the therapeutic